Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma-Possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: Report of the radiation therapy oncology group protocol 8302

International Journal of Radiation Oncology, Biology, Physics

Volumn 25, Issue 2, 1993, Pages 193-207

  Nelson, Diana Furst ^a   Curran Jr , Walter J ^b   Scott, Charles ^c   Nelson, James S ^d   Weinstein, Alan S ^e   Ahmad, Khurshid ^f   Constine, Louis S ^g   Murray, Kevin ^h   Powlis, William D ^b   Mohiuddin, Mohammed ⁱ   Fischbach, Jennifer ^j  

^a Highland Hospital Rochester   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^e Moorestown Medical Center ^*  (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j LDS HOSPITAL   (United States)

more..

Author keywords

Glioblastoma multiforme (GBM) and anaplastic astrocytoma; Hyperfractionated radiation therapy; Malignant (high grade) astrocytoma; Malignant glioma

Indexed keywords

CARMUSTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION NECROSIS;

ADULT; AGED; ASTROCYTOMA; CARMUSTINE; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SUPPORT, U.S. GOV'T, P.H.S.; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0027403895     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(93)90340-2     Document Type: Article

References (26)

1. Intracranial tumors: Response and resistance to therapeutic endeavors, 1970–1980
2. Regression models and life tables
3. A randomized I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥ 69.6 Gy in favorable patients with RTOG stage III non-small cell carcinoma of the lung. Report of Radiation Therapy Oncology Group 83-1l
4. Interfraction interval is major determinant of late effects, but not acute effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from Radiation Therapy Oncology Group Protocol 83-13
5. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma
6. 82Rb positron emission tomography
7. Fast neutron radiation therapy for glioblastoma multiforme: Results of an RTOG study
8. Nonparametric estimation from incomplete observations
9. The hazards of therapeutic irradiation of the central nervous system
10. Randomized neutron dose searching study for malignant gliomas of the brain: Results of an RTOG study
11. Hyperfractionated irradiation for adults with brainstem gliomas
12. Hyperfractionated radiotherapy for brainstem gliomas: The Memorial Sloan Kettering Cancer Center (MSKCC) experience (Abstr.)
13. Cerebral radionecrosis: Incidence and risk in relation to dose, time, fractionation and volume
14. Combined modality approach to treatment of malignant gliomas. Reevaluation of RTOG 7401/ECOG 1374 with long-term follow-up: A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study
15. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study
16. A randomized comparison of misonidazole sensitized radiother apy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Preliminary results of an RTOG study
17. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas
18. Results of a pilot study of hyperfractionated radiation therapy for children with brain stem gliomas
19. Radiation therapy of brain tumors
20. Therapeutic irradiation and brain injury
21. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships
22. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial
23. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
24. The randomization and stratification of patients to clinical trials